RJFSA
GALT icon

Raymond James Financial Services Advisors’s Galectin Therapeutics GALT Stock Holding History

Raymond James Financial Services Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-18,229
Closed -$41K – 3220
2020
Q4 		$41K Buy
+18,229
New +$47.8K ﹤0.01% 2925
2018
Q3 		– Sell
-10,733
Closed -$68K – 2849
2018
Q2 		$68K Buy
+10,733
New +$52.3K ﹤0.01% 2649

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Raymond James Financial Services Advisors's GALT Position: Q1 2021 in Review

Raymond James Financial Services Advisors sold out of Galectin Therapeutics (GALT) in Q1 2021, closing a stake of 18,229 shares — an estimated $41K sold.

Raymond James Financial Services Advisors first reported a position in GALT in Q2 2018 and held it in 2 quarters. The position peaked at $68K in Q2 2018. 75 funds tracked by Wall St. Rank hold GALT as of Q1 2021.

  • Raymond James Financial Services Advisors reported no remaining Galectin Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 18,229 Galectin Therapeutics shares in Q1 2021, an estimated $41K.
  • Raymond James Financial Services Advisors first reported a position in Galectin Therapeutics in Q2 2018 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Galectin Therapeutics position peaked at $68K in Q2 2018.
  • 75 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2021, filed 14 May 2021.